NCT03942653View on ClinicalTrials.gov

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 30, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Salivary Gland Carcinoma
Interventions
DRUG

Goserelin Acetate

Goserelin Acetate, SQ, Q4W

DRUG

Pembrolizumab

Pembrolizumab, IV, Q3W

Trial Locations (7)

21201

RECRUITING

Univeristy of Maryland, Baltimore

48109

RECRUITING

University of Michigan Health System, Ann Arbor

52242

RECRUITING

University of Iowa Hospitals and Clinics, Iowa City

53705

RECRUITING

University of Wisconsin, Madison

55455

RECRUITING

University of Minnesota: Masonic Cancer Center, Minneapolis

60611

RECRUITING

Northwestern University Feinberg School of Medicine, Chicago

60612

RECRUITING

University of Illinois Cancer Center, Chicago

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Manish Patel

OTHER

NCT03942653 - Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | Biotech Hunter | Biotech Hunter